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A number of potential anti-diabetic plants were identiﬁed through an ethnobotanical survey of the traditional pharmacopeia of
the Cree of Eeyou Istchee (CEI—Northeastern Canada) used against symptoms of diabetes and their biological activity assessed
by in vitro bioassays. Among these, Sorbus decora C.K.Schneid. (Rosacea) ranked highly and increased the transport of glucose
in skeletal muscle cells in culture. The present study thus aimed at conﬁrming the antidiabetic potential of S. decora in in vivo
models of insulin resistance and diabetes, notably the streptozotocin Type 1 diabetic rat (STZ), the genetic KK-A
y Type 2 diabetic
mouse and the rat rendered insulin resistant with 10% glucose water consumption for 6 weeks. Sorbus decora ethanolic crude
extract (SDEE) was administered orally (200mgkg
−1) and compared to metformin (150 or 500mgkg
−1). The intragastric (i.g.)
gavage of SDEE transiently decreased glycemia in STZ rats in a bi-phasic manner but the eﬀect was cumulative over several days.
In KK-A
y mice, SDEE incorporated in food (0.12%) decreased glycemia by 15% within 1 week as compared to vehicle controls.
In pre-diabetic insulin-resistant rats, SDEE fed daily by i.g. gavage for 2 weeks signiﬁcantly decreased the slight hyperglycemia
and hyperinsulinemia, without aﬀecting sugar water intake. Using the HOMA insulin resistance parameter, the eﬀe c to fS D E Ew a s
equivalent to that of metformin. In conclusion, the ethanolic crude extract of S. decora demonstrates both anti-hyperglycemic and
insulin-sensitizing activity in vivo, thereby conﬁrming anti-diabetic potential and validating CEI traditional medicine.
1.Introduction
Diabetes mellitus is a metabolic disease characterized by
hyperglycemia resulting from defects in insulin secretion,
insulin action or both. Type 1 diabetes is caused by a
deﬁciencyofinsulinsecretionfromβ-pancreaticcells.Onthe
other hand, Type 2 diabetes is closely associated with obesity
and is characterized by an initial phase of progressive insulin
resistance, with an ensuing reduction in the ability of the
pancreatic hormone to promote peripheral glucose disposal
and to suppress hepatic glucose output [1]. Sedentary life
style, unhealthy dietary habits and genetic predisposition are
some of the key factors that have conspired to create the cur-
rentworldwideepidemicofType2diabetes,anacquiredsyn-
drome of elevated blood glucose. In 2005, 246 million people
worldwide suﬀered from Type 2 diabetes and this number
is projected to grow to 366 million by 2030 [2], partly due
toincreasedobesity.Aboriginalpopulationsworldwide,such
as the Cree of Eeyou Istchii (CEI—from James Bay region
of the Canadian province of Quebec), are particularly at
risk. Indeed, CEI communities are more aﬀected by obesity
(30.1% versus 14.0%) and Type 2 diabetes (14.5% versus
4.1%)thantherestofCanada[3].Compoundingthelifestyle
changes and genetic predisposition, modern medicine and
its therapeutic arsenal are disconnected from CEI culture.
Drug treatment compliance is thus less than optimal and2 Evidence-Based Complementary and Alternative Medicine
diabetes complications therefore also more prevalent [3]. In
an eﬀort to develop culturally adapted complementary and
alternative therapies based on CEI traditional medicine, our
Team has identiﬁed several medicinal plants of the Boreal
forest used to treat several symptoms of diabetes [4]. A
number of these were conﬁrmed to have signiﬁcant anti-
diabetic potential when screened using in vitro bioassays
[5]. Among these, the ethanolic crude extract of Sorbus
decora C. K. Schneid. (Rosacea) showed eﬀectiveness in
increasing glucose uptake in skeletal muscle cells (C2C12)
[5]. The aim of this study was to conﬁrm the anti-diabetic
activity of S. decora in vivo. We used three animal models
of diabetes mellitus, in order to comprehensively evaluate
the impact of the ethanolic crude extract of S. decora on
several pathological states related to diabetes. Namely, Type
1 diabetes was induced by streptozotocin (STZ), a nitrosurea
derivative isolated from Streptomyces achromogenes able to
induce speciﬁc destruction of β-pancreatic cells in rats,
thus representing a typical model of insulin dependence.
Second, we studied eﬀects of S.decora in a pre-diabetic
insulin resistance model, induced in rats with a 10% glucose
solution as drinking water [6, 7]. Finally, we used the Type
2 diabetic KK-Ay mouse, a hyperphagic obese strain that
develops insulin resistance, compensatory hyperinsulinemia
and islet cell hyperplasia [8].
2. Methods
2.1. Animals. Male Sprague-Dawley (SD) rats (weighting
200–250g) were obtained from Charles River (St Constant,
Qu´ ebec, Canada), housed 1 per cage and allowed 1 week
to adapt to their new environment. The KK-Ay mice were
obtained from an in-house colony developed from breeding
pairs acquired from Jackson Laboratories (Bar Harbour, ME,
USA) and housed individually. The animals were maintained
in an environment of controlled temperature (20
◦C) and
humidity (53%) under a 12h light-dark cycle. For rats,
standard rodent chow and water were provided ad libitum
throughout the experimental period. KK-Ay mice were
treated similarly except during the treatment period, when
theyreceived the plant incorporated in the chow (see“in vivo
treatment administration” below). All animal procedures
used were in strict accordance with the Canadian Council
on Animal Care Guide to the Care and Use of Experimental
Animals and all experimental protocols were approved by
the Universit´ ed eM o n t r ´ eal animal experimentation ethics
committee.
2.2. Plant Material. The plant S. decora C.K. Schneid.
(Rosaceae) was harvested in Mistissini, Quebec, Canada, as
previously described [5] and by following the instructions of
the elders and healers of this community. The identiﬁcation
of the plant was conﬁrmed by taxonomist Dr A. Cuerrier
and a specimen was deposited in the Marie-Victorin herbar-
ium of the Montreal Botanical Garden, Montreal, Quebec,
Canada (number: MIS 03-9).
2.3.PreparationoftheEthanolicCrudeExtract. Theplantwas
air dried at the University of Ottawa and inner bark was
extracted twice with 10ml of 80% ethanol per gram for dry
material on a mechanical shaker for 24h, and then ﬁltered
using Whatman paper. The ﬁrst and the second extracts were
combined and dried in a rotatory evaporator followed by
lyophilization andpreservedat4◦Candp r ot ect edfr o mlight.
2.4. Induction of Diabetes Mellitus . Type 1 diabetes was
inducedbyasingleintraperitoneal(i.p.)injectionof100μlof
sterile phosphate buﬀered solution (PBS—pH 7.4) contain-
ing streptozotocin (STZ) (65mgkg
−1), (Zanosar, Pharmacia
& Upjohn, ON, Canada) and after 4 days the hyperglycemia
was established [9]. Glucose concentration was measured
in a blood sample obtained from tail puncture, with a
glucose oxidase-impregnated test strip and a reﬂectance
meter (Accu-Check III, Boehringer Mannheim, Germany).
Only animals that had a blood glucose concentration higher
than 20mM 4 days after treatment with STZ were used
for the study [9], generally >80% of STZ treated animals.
Control rats were injected with PBS only.
2.5. Induction of Insulin Resistance. Insulin resistance was
induced as detailed by El Midaoui [6, 7]w i t hs o m e
modiﬁcations. The insulin-resistant group of animals was
given a solution of 10% d-glucose as drinking water and
a normal chow diet during 6 weeks. Control animals were
fed for 6 weeks with tap water and normal chow diet. At
the end of the treatment period, blood was collected for the
subsequent measurement of glucose and insulin in animals
fasted for 16h. The plasma glucose concentration was
measured with a glucometer (Accu-Check III, Boehringer
Mannheim, Germany) and insulin levels were determined
by radioimmunoassay method (Rat Insulin RIA kit, Linco
Research, St Charles, MO, USA). To evaluate the degree
of insulin resistance, the Homeostasis Model Assessment
(HOMA) was used as an index of insulin resistance and
calculatedbythefollowingformula:insulin(μUml −1)×glu-
cose (mol l−1)/22.5 [6, 7]. Only animals that demonstrated a
signiﬁcant level of insulin resistance after 4 weeks of the 10%
glucosewatertreatmentwereselectedforthestudy(generally
80% of the treated animals).
2.6. KK-Ay—GeneticModelofType2Diabetes. The insertion
of the yellow agouti gene (Ay) into KK mouse strain results
inacongenicyellowobeseKKmousestrain,theKK-Ay mice.
It represents a genetic model of Type 2 diabetes that exhibit
severe obesity, hyperinsulinemia and insulin resistance, all
cardinal features of Type 2 diabetes [10].
2.7. In Vivo Treatment Administration. Preliminary experi-
ments were carried out with several vehicles to administer
the crude plant extract to animals, including 80% ethanol
or a mixture of 5% Tween and 5% ethanol in distilled
water. The latter two vehicles gave optimal results. In
rats, S. decora ethanolic crude extract (200mgkg−1)w a s
administered by intra-gastric gavage, either as a single dose
(acute treatment) or as a repeated daily administration over
7–14 days (chronic treatment), as reported by others [11].
Metforminwasusedasapositivecontrolatdosesdetermined
to be optimal in preliminary studies (500mgkg−1 in STZEvidence-Based Complementary and Alternative Medicine 3
rats and 150mgkg−1 in insulin-resistant rats) and was
also administered by intragastric (i.g.) gavage in conditions
identical to S. decora-treated congeners. Appropriate vehicle
controlswerealsousedinparallelrespectingstrictlyidentical
experimental protocols. Because i.g. gavage is more diﬃcult
and stressful for mice, KK-Ay animals received S. decora
ethanolic crude extract mixed in powdered rodent chow
at 0.12% and reconstituted into pellets. This dose was
determined to be equivalent to 200mgkg
−1 based on the
measured daily food consumption of the animals.
2.8. Statistical Analysis. Results are given as means ± SEM.
The signiﬁcance of diﬀerences between means was evaluated
by Student’s t-test or one-way analysis of variance (ANOVA),
asappropriate,followedbyposthoc Neuwman-Keulsanalysis
using StatView software version 4.01 (Cary, NC, USA). P-
values < 0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Sorbus decora Reduces Glycemia in Streptozotocin Type
1D i a b e t i cR a t s .We ﬁrst used streptozotocin (STZ)-treated
ratstoassessthehypoglycemicactivityofthecrudeethanolic
extract of S. decora (200mgkg−1, i.g.) in this Type 1 diabetes
setting. As shown in Figure 1(a), a single i.g. administration
of S. decora extract signiﬁcantly decreased glycemia in a bi-
phasic manner with peaks at 4h (9.7 ± 3.7% inhibition)
and 30h (14.4 ± 4.2% inhibition) as compared with vehicle-
treated animals. The 80% ethanol vehicle also yielded a
small and transient decrease in glycemia similar to that
seen for the initial peak observed with S. decora ethanolic
crude extract. However, its extent was signiﬁcantly lower
than that of S. decora and no second decrease was observed.
This was conﬁrmed by measuring the area above the
glycemia versus time curve using initial glycemia as the
baseline reference (Figure 1(b)). As a positive control, we
used the oral hypoglycemic drug metformin (optimal dose
of 500mgkg−1 in this model, i.g.); it induced a dramatic
drop in STZ rat glycemia that was monophasic and also
peaked at 4h. We next evaluated the impact of repeated
daily gavage of our treatments on STZ rat glycemia. As
shown in Figure 2(a),d a i l yS. decora ethanolic crude extract
treatment yielded the expected initial transient decrease
in plasma glucose just described. However, as treatment
days advanced, peak decreases in glycemia gradually reached
greater intensity, suggesting a cumulative eﬀect. In contrast,
repeatedmetformintreatmentyieldedsimilarlargedecreases
in STZ rat glycemia irrespective of the number of days of
i.g. administration. This was conﬁrmed by the area above the
c u r v ea n a l y s i s( Figure 2(b)).
3.2. Sorbus decora Improves Insulin Sensitivity in Insulin-
Resistant Rats. The second animal model used to assess
S. decora anti-hyperglycemic potential in vivo was the rat
insulin resistance model based on chronic treatment with
d-glucose (10%) in drinking water. As previously reported
[6, 7], chronic glucose water feeding more than doubled the
daily water intake (milliliters per day) as compared to rats
Sorbus decora
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Figure 1: Sorbus decora extract acutely decreases glycemia in Type
1 diabetes in a bi-phasic manner. (a) Glucose concentrations were
measured in the plasma of STZ diabetic rats pre-treated orally with
vehicle (80% ethanol in distilled water), S. decora (200mgkg−1)
or metformin (500 mg kg−1). (b) The area above the glycemia
versus time curve was assessed relative to initial glycemia used as
the baseline reference. Data are presented as means ± SEM (n = 6).
Signiﬁcantly diﬀerent from the vehicle-treated group,
∗P<. 05 or
∗∗P<. 01
receivingdailyi.g.administrationofvehicle(5%ethanol,5%
T ween80indistilledwat er —Figure 3).Moreover,dailytreat-
ment with ethanolic crude extract of S. decora (200mgkg−1
day−1,i.g.)ormetformin(optimaldoseof150mgkg−1 day−1
in this model, i.g.) for the last 2 weeks of a 6-week chronic
glucose water-feeding regimen did not aﬀect daily water
consumption. Eﬀects of the treatment regimens on fasting
blood glucose are presented in Figure 4. Chronic glucose
water feeding resulted in a modest but statistically signiﬁcant
increase in glycemia as expected in this insulin-resistant
model [6, 7]. This modest hyperglycemia was eﬀectively
and similarly normalized by either S. decora or metformin
treatments (Figure 4). This insulin-resistant model is also
characterizedbymodesthyperinsulinemia[6,7],asobserved4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of repeated oral treatment with S. decora ethanolic
crude extract on glycemia in Type 1 diabetes: evidence of a
cumulative eﬀect. (a) Glucose concentrations were measured in
the plasma of STZ diabetic rats treated orally in a repeated daily
manner with vehicle (80% ethanol in distilled water), S. decora
(200mgkg−1) or metformin (500mgkg−1). (b) The area above the
glycemia versus time curve was assessed relative to initial glycemia
used as the baseline reference. Data are presented as means ± SEM
(n = 6). Signiﬁcantly diﬀerent from vehicle-treated group,
∗P<. 05
or
∗∗P<. 01.
herein in vehicle-treated animals compared to normal non-
glucose-fed controls (Figure 5). A 2-week treatment with the
ethanolic crude extract of S. decora was eﬀective in reducing
insulinemia below the level of non-glucose-fed controls.
Metformin brought circulating insulin levels back toward
levelsfoundinnon-glucose-fedratcongeners.However,data
variabilitypreventedtheassignmentofstatisticalsigniﬁcance
to these ﬁndings (ANOVA NS). Nonetheless, when the
homeostasis model assessment (HOMA) insulin-resistance
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Figure 3: Eﬀect of S. decora ethanolic crude extract on water intake
in glucose-fed rats. Water intake was measured daily in rats fed with
a solution of 10% glucose or tap water (control) for 6 weeks and
treated daily with an oral administration of either vehicle (black
bar), S. decora (200mgkg−1) or metformin (150mgkg−1) during
the last 2 weeks of treatment. Data are presented as means ±
SEM (n = 6). Signiﬁcantly diﬀerent from vehicle treated animals,
∗∗∗P<. 001.
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Figure 4: Eﬀect of S. decora ethanolic crude extract on glycemia
in glucose-fed rats. Glucose concentrations were measured in the
plasma of rats fed with a solution of 10% glucose or tap water
(control) for 6 weeks and treated daily with an oral administration
of either vehicle (black bar), S. decora (200mgkg−1)o rm e t f o r m i n
(150mgkg−1) during the last 2 weeks of treatment. Data are
presented as means ± SEM (n = 6). Signiﬁcantly diﬀerent from
vehicle-treated group,
∗∗P<. 05 or
∗∗∗P<. 01.
index was evaluated, results were very convincing. Indeed,
as expected, chronic glucose feeding resulted in a large
and signiﬁcant increase in HOMA values as compared to
normal water-fed rats (Figure 6). Treatment with both the
ethanolic crude extract of S. decora and metformin was
eﬀective in reducing HOMA values back to levels observed
in normal animals, with a tendency for the plant extract to
have a greater eﬀect than the reference oral hypoglycemic
drug (Figure 6), thereby conﬁrming results on glycemia and
insulinemia.Evidence-Based Complementary and Alternative Medicine 5
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Figure 5: Eﬀect of S. decora extract on insulinemia in glucose-
fed rats. Insulin concentrations were measured by RIA in the
plasma of rats fed with a solution of 10% glucose or distilled water
(control) for 6 weeks and treated daily with an oral administration
of either vehicle (black bar), S. decora (200mgkg−1)o rm e t f o r m i n
(150mgkg−1) during the last 2 weeks of treatment. Data are
presented as means ± SEM (n = 6).
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Figure 6: Eﬀect of S. decora extract on insulin resistance in glucose-
fed rats. The homeostasis model assessment of insulin resistance
(HOMA) were measured in the plasma of rats fed with a solution
of 10% glucose or tap water (control) for 6 weeks and treated
daily with an oral administration of either vehicle (black bar), S.
decora (200mgkg−1) or metformin (150mgkg−1) during the last
2 weeks of treatment. Data are presented as means ± SEM (n
= 6). Signiﬁcantly diﬀerent from vehicle-treated group,
∗P<. 05,
∗∗P<. 01 or
∗∗∗P<. 001.
3.3. Eﬀects of S. decora in KK-Ay Type 2 Diabetic Mice.
Lastly, we used the KK-Ay g e n e t i c a l l yo b e s em o u s ea sa
model of full-blown hyperglycemic Type 2 diabetes. Diabetic
KK-Ay mice received the ethanolic crude extract of S. decora
mixed in food at 0.12% (to deliver 200mgkg−1 day−1)
during 7 days. Incorporation into food was chosen over i.g.
administration in order to avoid the larger stress of gastric
administration in these smaller animals. Blood glucose levels
decreased in S. decora-treated mice within 4 days of the onset
of treatment (Figure 7) and remained depressed thereafter.
In comparison, control KK-Ay fed normal laboratory chow
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Figure 7: Eﬀect of chronic treatment with S. decora extract in
Type 2 diabetic KK-A
y mice. (a) Blood glucose concentrations were
measured in animals receiving regular chow (control) or S. decora
mixed in chow at 0.12%. (b) The area below or above the glycemia
versustimecurvewasassessedrelativetoinitialglycemiausedasthe
baseline reference. Data are presented as means ± SEM (n = 6).
exhibited a stable glycemia over the 7-day experimental
period.
4. Discussion
The Cree people of Eeyou Istchee (CEI) in northern
Quebec, like most other North American tribes, have faced
signiﬁcant and rapid changes in their lifestyle including
reduced physical activity and increased consumption of
non-traditional foods [12, 13]. As a consequence, obesity
and diabetes are now highly prevalent in CEI, whereas
t h e yw e r em u c hl e s sf r e q u e n to n l y2 5y e a r sa g o .I n d e e d ,
although the life expectancy of First Nations people is still
the same as the whole of Canada (75.5 and 77.7 years),
the CEI population is 2.15 times more obese and has 3.5
times more diabetic than non-aboriginals in Canada [3].
Aside from genetic and environmental factors, the cultural
disconnect of modern pharmaceutical interventions leads6 Evidence-Based Complementary and Alternative Medicine
to less compliance to diabetes treatments and consequently
greater rates of diabetes complications, notably diabetic
neuropathy and nephropathy [3]. Multimodal interventions,
most notably those that are culturally better adapted, are
therefore urgently needed.
To address this, a multidisciplinary community-based
project was put in place joining three Canadian universities
(Montreal, McGill and Ottawa) with the Cree Board of
Health and Social Services and a number of Cree com-
munities in an eﬀort to explore the potential beneﬁt of
including Boreal forest plants stemming from Cree tradi-
tional medicine as part of such multimodal interventions. A
novel ethnobotanical approach based on diabetes symptoms
successfully identiﬁed potential anti-diabetic plants [4],
whose biological activity was conﬁrmed by a platform
of antidiabetic cell-based bioassays [5]. Among the most
promising plants was S. decora. Indeed, in vitro studies
demonstrated that the ethanolic crude extract of the S.
decora was able to increase glucose uptake in muscle cells
and to protect preneuronal PC12 cells against high glucose
conditions, highlighting the anti-diabetic properties for S.
decora [5]. In the present study, we used three diﬀerent
diabetic experimental models (pre-diabetic, Types 1 and
2 diabetes) to conﬁrm in vivo the anti-diabetic activity
demonstrated by S. decora from in vitro assays.
The rat pre-diabetic model chosen is characterized
by modest hyperinsulinemia and hyperglycemia secondary
to insulin resistance [6, 7]. Our results clearly showed
that daily i.g. treatment with the ethanolic crude extract
of S. decora during last 2 weeks of the 6-week glucose
feeding regimen gave results equivalent to the reference
oral hypoglycemic drug metformin. Indeed, both treatments
signiﬁcantly reduced glycemia as well as the HOMA insulin
resistance index without aﬀecting glucose water intake or
body weight.
Similar encouraging results were obtained in the strep-
tozotocin-treated rat (4 days), a model of Type 1 diabetes.
This model is much more severe with circulating glucose
in the 25–30mM range and severely deﬁcient pancreatic β-
cell function [9]. Despite the severity of the disease, the
acute administration of the crude ethanol extract of S. decora
succeeded in signiﬁcantly reducing blood glucose in a bi-
phasic manner by 10%–15%. When such administration
was repeated over several days, a cumulative eﬀect was
suggested.Incomparison,metforminwasmuchmorepotent
at reducing the glycemia of STZ rats, but it did so in a
monophasic manner with no evidence of a cumulative eﬀect
over the experimental period used.
Finally, we used the KK-Ay mouse model that is char-
a c t e r i z e db yo b e s i t ya n de x p r e s s e ss e v e r eT y p e2d i a b e t e s
(glycemiaintherangeof20–25mM).Becausemicearemore
sensitive to needle i.g. gavage (stress having a major impact
onglycemiaintheseanimals;Brault,MartineauandHaddad,
unpublished observations), we incorporated the ethanolic
crude extract of S. decora into the diet of the animals. Over a
7-day period, glycemia had a tendency to diminish but data
variabilitypreventedtheassignmentofstatisticalsigniﬁcance
to this hypoglycemic eﬀect. It is possible that the dose was
not suﬃciently high, even though it was calculated to be
equivalent to the dose delivered to rats by i.g. gavage on a
daily basis. It must also be considered that rats and mice
may not express the same sensitivity to the plant extract.
Alternatively, bioavailability may have been lower in the
rodent chow matrix than in the solvents used for gavage,
especially since the intake of the extract was spread over the
feeding period as opposed to the bolus dose provided by
i.g. gavage. However, in our hands, metformin administered
through the diet completely normalizes glycemia in KK-Ay
mice over a 3-4-day period, as observed elsewhere [14].
Nevertheless, it remains possible that the treatment period
with S. decora ethanolic crude extract was not suﬃciently
long for glycemia to reach statistically lower levels, as
compared to control mice that had a very stable glycemia
over the 7-day regimen. Future studies should thus address
these considerations to conﬁrm the hypoglycemic action of
S. decora ethanolic crude extract in this animal model.
Recent studies in our laboratory indicate that S. decora
actsbyamechanismsimilartothatofmetformin.Metformin
is a dimethylbiguanide oral hypoglycemic drug derived
from guanidine, a hypoglycemic active compound isolated
from Galega oﬃcinalis [15] or French Lilac, a medicinal
plant used for centuries in Europe for diabetes treatment.
Metformin is widely prescribed for humans with Type 2
diabetes in the world [15]. It is able to inhibit hepatic
glucose production and also acts as an insulin sensitizer
in isolated skeletal muscle from insulin-resistant humans
[16]. It was demonstrated that the enzyme AMP-activated
kinase (AMPK) is activated by metformin [15–19]. AMPK
is a key sensor of cell energetic balance being activated
by increase in the ratio AMP/ATP. There are indications
that the activation of this enzyme is beneﬁcial for the
treatment and prevention of Type 2 diabetes and the
metabolicsyndrome[19–21];itsactivationleadstoincreased
glucose uptake in rat skeletal muscle [22]. Likewise, the
ethanolic crude extract of S. decora increases glucose uptake
in C2C12 cells by means of AMPK activation, which appears
to implicate the inhibition of mitochondrial respiration
[23]. These cellular and molecular actions may thus play a
signiﬁcant role in the hypoglycemic activity of the plant in
vivo.
In summary, taken together, all in vivo models of
insulin resistance and diabetes used herein conﬁrm the anti-
diabetic potential of S. decora, with a caveat that greater
eﬀects may be obtained in less severe stages of the disease.
The present studies, therefore, provide compelling scientiﬁc
evidence that plants used within the traditional medicine of
the CEI to treat diabetic symptoms do possess signiﬁcant
antidiabetic potential in animal models of diabetes. Plants
such as S. decora are currently used by Cree populations
of Mistissini without notable signs of toxicity (S. Grandi et
al., unpublished observations). Nonetheless, clinical studies
are required to assess the potential beneﬁt of using S.
decora preparations in humans. Our studies pave the way to
such studies and support the inclusion of such traditional
medicine as part of a multimodal set of interventions to help
Cree diabetics to manage their disease in a culturally relevant
manner.Evidence-Based Complementary and Alternative Medicine 7
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